中国单中心研究：阑尾黏液性腺癌伴腹膜转移的治疗与预后预测。

Management and prognostic prediction of appendiceal mucinous adenocarcinoma with peritoneal metastasis: a single center study in China.

机构信息

Department of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.

Department of Pathology, Aerospace Center Hospital, Beijing, China.

出版信息

BMC Cancer. 2020 Apr 6;20(1):280. doi: 10.1186/s12885-020-06787-4.

DOI:10.1186/s12885-020-06787-4

PMID:32252683

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7137227/

Abstract

BACKGROUND

To investigate the clinical and pathological characteristics of appendiceal mucinous adenocarcinoma with peritoneal metastasis and analyze the prognostic factors.

METHODS

A retrospective analyses of clinicopathological features of 50 patients with appendiceal mucinous adenocarcinoma with peritoneal metastasis from January, 2013 to December, 2017 in Aerospace Central Hospital, Beijing, China. Survival data calculation and comparison were respectively performed with the Kaplan-Meier method and the log-rank test. The Cox proportional hazards regression method was used for multivariate survival analyses.

RESULTS

Cytoreduction for appendiceal mucinous adenocarcinoma was conducted on 50 patients (24 males and 26 females), with a median age of 52.5 years at the time of surgery (range 31-71 years). The median overall survival (OS) time was 24 months, with 2-,3- and 5-year survival rates of 53, 24 and 8%, respectively. At the last follow-up in December 2018, 13 patients were still alive. Multivariate analysis revealed that patients who had low Ki-67 expression (less than 50%) and CCR (completeness of cytoreduction) 0/1/2 score had significantly better OS rate than their respective counterparts.

CONCLUSIONS

Ki-67 expression statue and CCR score could be employed as the prognosis prediction in patients with appendiceal mucinous adenocarcinoma.

摘要

背景

研究阑尾黏液腺癌伴腹膜转移的临床和病理特征，并分析其预后因素。

方法

回顾性分析 2013 年 1 月至 2017 年 12 月在北京航天中心医院收治的 50 例阑尾黏液腺癌伴腹膜转移患者的临床病理特征。采用 Kaplan-Meier 法和对数秩检验分别进行生存数据计算和比较，采用 Cox 比例风险回归法进行多因素生存分析。

结果

50 例患者（男 24 例，女 26 例）接受了阑尾黏液腺癌的细胞减灭术，手术时的中位年龄为 52.5 岁（范围 31-71 岁）。中位总生存期（OS）为 24 个月，2、3 和 5 年生存率分别为 53%、24%和 8%。截至 2018 年 12 月最后一次随访时，仍有 13 例患者存活。多因素分析显示，Ki-67 表达（<50%）和 CCR（细胞减灭术完全程度）评分 0/1/2 低的患者 OS 率显著高于相应的患者。